Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 288.80K | 347.00K | 432.10K | 603.70K | 634.40K |
| Depreciation & Amortization | 13.50K | 13.50K | 13.50K | 25.90K | 33.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 337.30K | 410.70K | 531.20K | 710.40K | 750.50K |
| Operating Income | -337.30K | -410.70K | -531.20K | -710.40K | -750.50K |
| Income Before Tax | -338.80K | -418.20K | -648.20K | -913.00K | -1.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.34 | -0.42 | -0.65 | -0.91 | -1.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 800.00 | 900.00 | 1.20K | 2.50K | 3.50K |
| Net Income | -338.00K | -417.20K | -646.90K | -910.50K | -1.09M |
| EBIT | -337.30K | -410.70K | -531.20K | -710.40K | -750.50K |
| EBITDA | -323.20K | -383.00K | -489.60K | -656.30K | -682.40K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 193.04M | 193.04M | 186.84M | 172.53M | 158.33M |
| Average Diluted Shares Outstanding | 193.04M | 193.04M | 186.84M | 172.53M | 158.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
